Cargando…

Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study

OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabo, Shelagh M, Gooch, Katherine, Schermer, Carol, Walker, David, Lozano-Ortega, G, Rogula, Basia, Deighton, Alison, Vonesh, Edward, Campbell, Noll
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502005/
https://www.ncbi.nlm.nih.gov/pubmed/31061036
http://dx.doi.org/10.1136/bmjopen-2018-026391
_version_ 1783416184080695296
author Szabo, Shelagh M
Gooch, Katherine
Schermer, Carol
Walker, David
Lozano-Ortega, G
Rogula, Basia
Deighton, Alison
Vonesh, Edward
Campbell, Noll
author_facet Szabo, Shelagh M
Gooch, Katherine
Schermer, Carol
Walker, David
Lozano-Ortega, G
Rogula, Basia
Deighton, Alison
Vonesh, Edward
Campbell, Noll
author_sort Szabo, Shelagh M
collection PubMed
description OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: United States, commercially and Medicare-insured population. PARTICIPANTS: 154 432 adults with OAB and 86 966 adults without OAB, mean age of 56 years, and 67.9% women. MAIN OUTCOME MEASURES: Cumulative anticholinergic burden, a unitless value representing exposure over time, was estimated over the 12 months pre-index (‘at baseline’) and every 6 months post index. Burden was categorised as no burden (0), low burden (1–89), medium burden (90–499) or high burden (500+). Unadjusted rates of falls or fractures were estimated, and the increased risk associated with anticholinergic burden (measured at the closest 6-month interval prior to a fall or fracture) was assessed using a Cox proportional hazards model and a marginal structural model. RESULTS: Median (IQR) baseline anticholinergic burden was 30 (0.0–314.0) and higher among older (≥65 years, 183 [3.0–713.0]) versus younger (<65 years, 13 [0.0–200.0]) adults. The unadjusted rate of falls or fractures over the period was 5.0 per 100 patient-years, ranging from 3.1 (95% CI 3.0–3.2) for those with no burden, to 7.4 (95% CI 7.1–7.6) for those with high burden at baseline. The adjusted risk of falls and fractures was greater with higher anticholinergic burden in the previous 6 months, with an HR of 1.2 (95% CI 1.2 to 1.3) for low burden versus no burden, to 1.4 (95% CI 1.3 to 1.4) for high versus no burden. Estimates from marginal structural models adjusting for time-varying covariates were lower but remained significantly higher with a higher anticholinergic burden. Rates of falls and fractures were approximately 40% higher among those with OAB (vs those without). CONCLUSION: Higher levels of anticholinergic burden are associated with higher rates of falls and fractures, highlighting the importance of considering anticholinergic burden when treating patients with OAB.
format Online
Article
Text
id pubmed-6502005
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65020052019-05-21 Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study Szabo, Shelagh M Gooch, Katherine Schermer, Carol Walker, David Lozano-Ortega, G Rogula, Basia Deighton, Alison Vonesh, Edward Campbell, Noll BMJ Open Pharmacology and Therapeutics OBJECTIVE: To estimate the association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder (OAB). DESIGN: A retrospective claims-based study (2007–2015) of patients with OAB; outcomes from a subset were contrasted to a non-OAB comparison. SETTING: United States, commercially and Medicare-insured population. PARTICIPANTS: 154 432 adults with OAB and 86 966 adults without OAB, mean age of 56 years, and 67.9% women. MAIN OUTCOME MEASURES: Cumulative anticholinergic burden, a unitless value representing exposure over time, was estimated over the 12 months pre-index (‘at baseline’) and every 6 months post index. Burden was categorised as no burden (0), low burden (1–89), medium burden (90–499) or high burden (500+). Unadjusted rates of falls or fractures were estimated, and the increased risk associated with anticholinergic burden (measured at the closest 6-month interval prior to a fall or fracture) was assessed using a Cox proportional hazards model and a marginal structural model. RESULTS: Median (IQR) baseline anticholinergic burden was 30 (0.0–314.0) and higher among older (≥65 years, 183 [3.0–713.0]) versus younger (<65 years, 13 [0.0–200.0]) adults. The unadjusted rate of falls or fractures over the period was 5.0 per 100 patient-years, ranging from 3.1 (95% CI 3.0–3.2) for those with no burden, to 7.4 (95% CI 7.1–7.6) for those with high burden at baseline. The adjusted risk of falls and fractures was greater with higher anticholinergic burden in the previous 6 months, with an HR of 1.2 (95% CI 1.2 to 1.3) for low burden versus no burden, to 1.4 (95% CI 1.3 to 1.4) for high versus no burden. Estimates from marginal structural models adjusting for time-varying covariates were lower but remained significantly higher with a higher anticholinergic burden. Rates of falls and fractures were approximately 40% higher among those with OAB (vs those without). CONCLUSION: Higher levels of anticholinergic burden are associated with higher rates of falls and fractures, highlighting the importance of considering anticholinergic burden when treating patients with OAB. BMJ Publishing Group 2019-05-05 /pmc/articles/PMC6502005/ /pubmed/31061036 http://dx.doi.org/10.1136/bmjopen-2018-026391 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Pharmacology and Therapeutics
Szabo, Shelagh M
Gooch, Katherine
Schermer, Carol
Walker, David
Lozano-Ortega, G
Rogula, Basia
Deighton, Alison
Vonesh, Edward
Campbell, Noll
Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title_full Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title_fullStr Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title_full_unstemmed Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title_short Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study
title_sort association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: us-based retrospective cohort study
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502005/
https://www.ncbi.nlm.nih.gov/pubmed/31061036
http://dx.doi.org/10.1136/bmjopen-2018-026391
work_keys_str_mv AT szaboshelaghm associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT goochkatherine associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT schermercarol associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT walkerdavid associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT lozanoortegag associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT rogulabasia associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT deightonalison associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT voneshedward associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy
AT campbellnoll associationbetweencumulativeanticholinergicburdenandfallsandfracturesinpatientswithoveractivebladderusbasedretrospectivecohortstudy